Burosumab (Anti-FGF23)

Synonyms: KRN23

Catalog No.A2499 Purity:99%

Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD.

Purity & Quality Control

Batch: A249901 Purity: 99% Protein concentration: 5.19mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective FGFR Inhibitors

Name	Citation	FGFR	FGFR1	FGFR2	FGFR3	FGFR4	Others
PD173074	120		++				VEGFR2
Dovitinib (TKI-258)	49		+++		+++		FLT3,c-Kit,VEGFR3/FLT4
Fexagratinib (AZD4547)	135		++++	++++	++++		KDR
Danusertib (PHA-739358)	46		++				Aurora A,Abl,TrkA
Brivanib (BMS-540215)	9		+				VEGFR2,Flk1,VEGFR1
ENMD-2076	8		+	+			FLT3,RET,Aurora A
MK-2461	4		+	++	++		c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
Brivanib Alaninate (BMS-582664)	2		+				VEGFR2,Flk1,VEGFR1
Tyrphostin AG 1296	14	+					PDGFR,c-Kit (Swiss 3T3)
SSR128129E	9		+
R1530	0		++				VEGFR2
FIIN-3	0		+++	++	++	++
Lucitanib (E3810) hydrochloride	1		++	+			VEGFR1,VEGFR3,VEGFR2
Sulfatinib	1		+++				VEGFR3,VEGFR1,CSF1R
ODM-203	0		+++	+++	+++	++	VEGFR3,VEGFR2,VEGFR1
Futibatinib (TAS-120)	14		++++	++++	++++	+++
ASP5878	3		++++	++++	++++	+++
Derazantinib	4		+++	++++	+++	++	RET,DDR2,PDGFRβ
H3B-6527	11					++++
Roblitinib (FGF401)	4					++++
PRN1371	2		++++	++++	+++	++	CSF1R
PD-166866	12		+
Fisogatinib (BLU-554)	8					+++
S49076	1		++	++	+++		Met,Mer,Axl
NSC12	2			+			FGF3,FGF8b,FGF22
ON123300	3		++				CDK4/CyclinD1,RET,CDK6/CyclinD1
SU5402	17		++				VEGFR2,PDGFRβ
BLU9931	18				+	+++
FIIN-2	4		+++	+++	++	++
Dovitinib (TKI258) Lactate monohydrate	30		+++		+++		FLT3,c-Kit,VEGFR3/FLT4
Zoligratinib (Debio-1347)	11		+++	+++	++	+
LY2874455	14		+++	+++	+++	+++	VEGFR2
Ferulic Acid	6		+	+
Lirafugratinib			✔
Masitinib mesylate				✔		FAK,human recombinant c-Kit,LynB
BO-264				✔		TACC3
SKLB 610			✔			PDGFR,VEGFR2
Alofanib (RPT835)			✔
Gambogenic acid	✔					EZH2

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1610833-03-8
Molecular Weight	144 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.